TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Employing cutting-edge technology, we innovate to help patients with differentiated and affordable biologics.
Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.
Our translational research platform enables us to model tumor responses to our investigational agents and to better understand PK/PD profiles, which guides design and conduct of clinical study.
We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.
Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.
Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.
Benefited from the global network and industry resources of our prominent shareholders with deep biotech expertise, we have forged multiple forms of important strategic cooperation with leading domestic and international pharmaceutical companies and equipment suppliers.
